SAN FRANCISCO--(BUSINESS WIRE)--April 25, 2006--NeoPharm, Inc. (Nasdaq:NEOL - News):
Phase I Study Confirms Combination Therapy that Includes Cintredekin Besudotox May Be An Option For This Patient Population. NeoPharm, Inc. (Nasdaq:NEOL - News) today announced that, based upon a recent Phase I study, evidence was provided that cintredekin besudotox (IL13-PE38QQR) appears to be safe and well tolerated in newly diagnosed malignant glioma patients. Results from the Phase I study will be presented at the 74th Annual Meeting of the American Association of Neurological Surgeons (AANS) held in San Francisco on Tuesday, April 25, 2006.
